March 16, 2026--Today, Eli Lilly and Company announced that access to self-pay pricing on the new Zepbound® (tirzepatide) KwikPen® for single-patient use will be available at LillyDirect® and major pharmacies nationwide, starting at $299 per month for the 2.5 mg dose. This expansion provides people without obesity management medicine insurance coverage with additional ways to access prescribed treatment, whether that’s picking up a prescription as part of their everyday routine at a local pharmacy, or choosing home delivery through LillyDirect.
The new KwikPen Self-Pay Savings Card, found on zepbound.lilly.com/savings, is available to all patients, including those without insurance coverage. Adults with a valid, on‑label prescription for Zepbound KwikPen can use the savings card to access the same self‑pay prices offered through LillyDirect. To understand your coverage options, visit zepbound.lilly.com/savings.
The card applies only to the Zepbound KwikPen and does not apply to single-dose vials or the single-dose pen.
Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children. Please see Indications and Safety Summary with Warnings below.
Zepbound is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg doses. The 2.5 mg is a starting dose and not an approved maintenance dose. The recommended maintenance doses are 5 mg, 10 mg, or 15 mg injected subcutaneously once per week for weight reduction and long-term maintenance. The recommended maintenance doses for OSA are 10 mg or 15 mg.
About Zepbound (tirzepatide) injection
Zepbound is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced-calorie diet and increased physical activity. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.
About LillyDirect
LillyDirect is a digital health platform designed to connect people living with chronic conditions to the care, support, and prescribed medicines they need. The platform brings together disease specific resources, access to independent healthcare providers, and convenient pharmacy services to help patients navigate their care. Prescription fulfillment through LillyDirect is open to all U.S. healthcare providers licensed to prescribe Lilly medicines and is listed as a pharmacy option in all major electronic health records (EHR) systems.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.